Search
Eptifibatide
go.drugbank.com/drugs/DB00063ApprovedInvestigationalSynthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide th...
Creatine
go.drugbank.com/drugs/DB00148ApprovedInvestigationalNutraceuticalAn amino acid derivative that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as creatinine in the urine.
Docosanol
go.drugbank.com/drugs/DB00632ApprovedDocosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters). A saturated 22-carbon aliphatic alcohol, docosanol exhibits antiviral activity against many lipid e...
ALT-2074
go.drugbank.com/drugs/DB05631InvestigationalAn organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated.
IC41
go.drugbank.com/drugs/DB05776InvestigationalIt is being devloped by Intercell AG for the treatment of hepatitis C.
rhIGFBP-3
go.drugbank.com/drugs/DB05897InvestigationalIt is developed by Insmed and is currently under phase I of the clinical trial.
alpha-Hydroxy glycineamide
go.drugbank.com/drugs/DB06568ExperimentalAlpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid
Phosphoaminophosphonic acid guanylate ester
go.drugbank.com/drugs/DB02082ExperimentalA non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+.
Zebularine
go.drugbank.com/drugs/DB03068ExperimentalIt acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates.
RGX-181
go.drugbank.com/drugs/DB17942ExperimentalDeveloped by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.[L47072]